Torrent Pharmaceuticals Limited has informed the Exchange about Investor Presentation
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals submitted its investor presentation on audited results for Q4 FY25 and the full financial year ended 31st March 2025. Total Q4 revenue rose 8% year-on-year to Rs 2,959 crore, driven by strong growth in India (12% to Rs 1,545 cr) and the United States (15% to Rs 302 cr). For the full year FY25, total revenue grew 7% to Rs 11,516 crore, with India up 13% to Rs 6,393 crore and Germany up 6% to Rs 1,139 crore. The Brazil business remained a weak spot, declining 6% in Q4 and 2% for the full year. The presentation shared with exchanges covers only the revenue summary visible in the document.
Shareholders get a detailed look at the company's geographic revenue mix and growth trends, with India and US businesses leading the way while Brazil drags. The strong India growth may support positive investor sentiment, though absence of margin and profit details in the visible portion limits the full picture.